Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVASTIN vs ERLOTINIB HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Erlotinib is a tyrosine kinase inhibitor that reversibly inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby blocking downstream signaling pathways involved in cell proliferation and survival. It binds to the ATP-binding site of EGFR, preventing autophosphorylation and activation of downstream effectors such as PI3K/Akt and MAPK.
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (first-line, maintenance, or after progression on prior chemotherapy),Pancreatic cancer in combination with gemcitabine (first-line for locally advanced, unresectable, or metastatic disease),Off-label: advanced/metastatic NSCLC with EGFR mutations other than exon 19/21, head and neck squamous cell carcinoma, and other EGFR-expressing tumors
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
150 mg orally once daily on an empty stomach (at least 1 hour before or 2 hours after food).
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Terminal half-life approximately 36 hours (range 24-48 hours) in clinical setting, supporting once-daily dosing.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Erlotinib is extensively metabolized primarily by CYP3A4, with minor contributions from CYP1A2 and CYP1A1. Hepatic metabolism to O-desmethyl erlotinib (active metabolite) and other inactive metabolites.
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Primarily hepatic metabolism (CYP3A4), with fecal excretion as metabolites (83%) and renal excretion (8% as parent and metabolites).
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
Approximately 93% bound to albumin and alpha-1-acid glycoprotein.
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
Vd of 220-280 L (approx 3.5-4 L/kg for 70 kg adult), indicating extensive tissue distribution.
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
Oral bioavailability about 60% (increased to ~100% when taken with food, but avoid food to reduce variability).
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
No dose adjustment required for mild to moderate renal impairment. Not recommended for patients with severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
For patients with severe hepatic impairment (Child-Pugh class C), consider dose reduction to 75 mg orally once daily. Mild to moderate impairment (Child-Pugh A or B) does not require adjustment.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
Not recommended for pediatric patients; safety and efficacy not established.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
No specific dose adjustment recommended; identical dosing to younger adults, but monitor renal and hepatic function due to age-related changes.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
No FDA black box warnings.
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Interstitial lung disease (ILD)-like events, including fatalities,Hepatic impairment (increase toxicity, require dose adjustment),Renal failure (monitor renal function),Gastrointestinal perforation (rare but fatal),Bullous and exfoliative skin disorders (Stevens-Johnson syndrome/toxic epidermal necrolysis),Ocular toxicities (keratitis, corneal ulceration, perforation),Hemorrhage (including epistaxis, gastrointestinal bleeding),Embryofetal toxicity (cause fetal harm; advise contraception),Drug interactions with strong CYP3A4 inducers/inhibitors and proton pump inhibitors
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
Hypersensitivity to erlotinib or any component of the formulation
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
Take on an empty stomach: no food for at least 1 hour before or 2 hours after. Avoid grapefruit juice, grapefruit, and Seville oranges due to CYP3A4 inhibition increasing erlotinib exposure. Alcohol may increase risk of hepatotoxicity.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
Risk Category D. Based on animal studies and mechanism of action, erlotinib can cause fetal harm. There are no adequate and well-controlled studies in pregnant women. In postmarketing reports, spontaneous abortions and congenital anomalies have been observed. Risks by trimester: First trimester: potential for teratogenicity (oligohydramnios, skeletal abnormalities). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory distress.
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for 2 weeks after last dose.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
No specific dosing guidelines exist for pregnancy. Physiologic changes in pregnancy (increased Vd, renal clearance, hepatic metabolism) may reduce erlotinib exposure. Therapeutic drug monitoring is not standard. Use lowest effective dose; consider dose adjustments based on toxicity, not pregnancy alone. Monitor for lack of efficacy and adjust dose accordingly.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
Administer on an empty stomach (at least 1 hour before or 2 hours after food) to ensure consistent absorption. Monitor for interstitial lung disease (ILD) symptoms (dyspnea, cough, fever) and consider drug discontinuation. Erlotinib is a potent CYP3A4 inhibitor; avoid concurrent use with CYP3A4 substrates with narrow therapeutic index (e.g., simvastatin). Smoking induces CYP1A2 and reduces erlotinib exposure; advise smoking cessation and consider dose adjustment in smokers.
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
Take erlotinib at least 1 hour before or 2 hours after a meal with water.,Do not crush, chew, or split the tablet; swallow whole.,If you miss a dose, skip it and take the next dose as scheduled; do not double up.,Avoid grapefruit and Seville oranges (e.g., marmalade) as they may increase drug levels.,Contact your doctor immediately if you experience new or worsening shortness of breath, cough, or fever (signs of lung inflammation).,Use effective contraception during treatment and for at least 2 weeks after the last dose; erlotinib can harm a fetus.,Avoid smoking; it decreases drug effectiveness. Notify your doctor if you start or stop smoking.
No interactions on record
"Aprepitant is a substrate of CYP3A4, and erlotinib is a moderate inhibitor of CYP3A4. Co-administration may lead to increased aprepitant plasma concentrations, potentially augmenting its antiemetic effects and risk of side effects such as hiccups, fatigue, and dizziness. Conversely, aprepitant does not significantly affect erlotinib metabolism, but the interaction may require dose adjustments for aprepitant if toxicity emerges."
"Promethazine, a phenothiazine antihistamine with weak anticholinergic properties, can decrease the serum concentration of erlotinib, a tyrosine kinase inhibitor used in non-small cell lung cancer. This interaction likely results from promethazine inducing the activity of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for erlotinib metabolism, thereby accelerating its clearance. Reduced erlotinib exposure may compromise its anticancer efficacy, potentially leading to suboptimal therapeutic outcomes."
"Erlotinib, a tyrosine kinase inhibitor, is primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2. Verapamil, a moderate inhibitor of CYP3A4, can reduce the clearance of erlotinib, leading to increased plasma concentrations of erlotinib. This may potentiate erlotinib-related adverse effects such as diarrhea, rash, and hepatotoxicity, and requires dose modification or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVASTIN vs ERLOTINIB HYDROCHLORIDE, answered by our medical review team.
AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. ERLOTINIB HYDROCHLORIDE is a EGFR Inhibitor Antineoplastic that works by Erlotinib is a tyrosine kinase inhibitor that reversibly inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby blocking downstream signaling pathways involved in cell proliferation and survival. It binds to the ATP-binding site of EGFR, preventing autophosphorylation and activation of downstream effectors such as PI3K/Akt and MAPK.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVASTIN and ERLOTINIB HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. The standard adult dose of ERLOTINIB HYDROCHLORIDE is: 150 mg orally once daily on an empty stomach (at least 1 hour before or 2 hours after food).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVASTIN and ERLOTINIB HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. ERLOTINIB HYDROCHLORIDE is classified as Category C. Risk Category D. Based on animal studies and mechanism of action, erlotinib can cause fetal harm. There are no adequate and well-controlled studies in pregnant women. In postmarket. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.